Treatment Information

Back

Prostate Cancer treatment details. Biologic therapy.

Norris Comprehensive Cancer Center, Los Angeles, CA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Los Angeles, CA
Treatments:Biologic therapyHospital:Norris Comprehensive Cancer Center
Drugs:Journal:Link
Date:Jun 2010

Description:

Patients:
This phase II study involved 53 men with castration-resistant prostate cancer who had received previous chemotherapy. The median patient age was 71 years.

Treatment:
Patients were treated with the biologic therapy agent siltuximab, which is a monoclonal antibody that recognizes IL-6.

Toxicities:
The most severe adverse effect was grade 4 disseminated intravascular coagulation (blood clotting). Grade 3/4 pain and neuropathy was also reported.

Results:
The median overall survival was 11.6 months.

Support:
This study was partially supported by Centocor, Inc., makers of siltuximab.

Correspondence: Dr. Tanya B. Dorff; email: [email protected]



Back